脾脏酪氨酸激酶（SYK）：小分子抗肿瘤药物组合的新靶点

IF 4.9 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert opinion on investigational drugs Pub Date : 2024-08-03 DOI:10.1080/13543784.2024.2388559

Charanjit Kaur, Amandeep Thakur, Ke-Chi Liou, Neralla Vijayakameswara Rao, Kunal Nepali

引用次数: 0

摘要

脾酪氨酸激酶（SYK）是一种非受体酪氨酸激酶，已成为癌细胞生存和分裂的复杂交响乐中的重要组成部分。SYK的活化（组成型）是...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents

Spleen tyrosine kinase (SYK), a nonreceptor tyrosine kinase, has emerged as a vital component in the complex symphony of cancer cell survival and division. SYK activation (constitutive) is document...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.